Sirona Biochem Corp V.SBM

Alternate Symbol(s): SRBCF

Healthcare Biotechnology

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.

TSXV:SBM - Post by User

Sirona Biochem Corp > new sedar file "statement of executive compensation"

<< Previous

Bullboard Posts

Next >>

Post by noclue80on Apr 30, 2021 8:06am

331 Views

Post# 33099751

new sedar file "statement of executive compensation"

do you guys know whether this is an update to an existing agreement or a new one? surpised to see that change of control as well as buyout impact is regulated in detail here for Verrico and Hopton, but it might be standard to have this described anyway and does not mean there is something in the making..

https://sedar.com/GetFile.do?lang=EN&docClass=30&issuerNo=00025131&issuerType=03&projectNo=03212877&docId=4946576

<< Previous

Bullboard Posts

Next >>

A Look into the Future of Chronic Pain Management